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Preserving residual renal function has always been the
primary clinical goal for every nephrologist managing
patients with chronic kidney disease. There is no reason why
this important goal should not extend to patients with stage
5 chronic kidney disease receiving dialysis. Indeed, there is
now clear evidence that preserving residual renal function
remains important after the commencement of dialysis.
Residual renal function contributes significantly to the overall
health and well-being of dialysis patients. It not only provides
small solute clearance but also plays an important role in
maintaining fluid balance, phosphorus control, and removal
of middle molecular uremic toxins, and shows strong inverse
relationships with valvular calcification and cardiac
hypertrophy in dialysis patients. Decline of residual renal
function also contributes significantly to anemia,
inflammation, and malnutrition in patients on dialysis. More
importantly, the loss of residual renal function, especially in
patients on peritoneal dialysis, is a powerful predictor of
mortality. In addition, there is increasing evidence that
residual renal and peritoneal dialysis clearance cannot be
assumed to be equivalent qualitatively, thus indicating the
need to preserve residual renal function in patients on
dialysis. In this article, we will review evidence that residual
renal function is important in dialysis patients (especially
peritoneal dialysis) and outline potential strategies that may
better preserve residual renal function in dialysis patients.
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IMPORTANCE OF RESIDUAL RENAL FUNCTION ON SURVIVAL
OF DIALYSIS PATIENTS
The important association between residual renal function
and survival in dialysis patients was first reported in the mid
1990s by Maiorca et al.1 They evaluated residual renal
function as a separate factor and showed that the persistence
of residual renal function conferred survival benefit in
peritoneal dialysis patients.1 Several subsequent cohort
studies observed similar findings that residual renal function
but not the dose of peritoneal dialysis was a powerful
predictor of survival in patients on peritoneal dialysis.2,3 This
raised the need to review data from the original CANUSA
study, which assumed an equivalence of renal and peritoneal
dialysis clearance and showed that the total (sum of renal and
peritoneal dialysis) small solute clearance predicts mortality
in peritoneal dialysis patients.4 Indeed, reanalysis of data
from the CANUSA study clearly demonstrated that the
predictive power for mortality in patients on peritoneal
dialysis was attributed to residual renal function and not to
the dose of peritoneal dialysis.5 Although this should not lead
to the assumption that the dose of peritoneal dialysis is
unimportant, it does indicate that the contribution of
residual renal and peritoneal dialysis clearance to the survival
of peritoneal dialysis patients is not equivalent. On the other
hand, studies in hemodialysis patients have also reported
similar findings. An earlier network registry data from the
United States as well as the more recent Netherlands
Cooperative Study on the Adequacy of Dialysis (NECOSAD)
study indicated the important contribution of residual renal
function to the overall survival of hemodialysis patients.6,7
The recent ADEquacy of Peritoneal Dialysis in MEXico
(ADEMEX) study lent further important evidence that
residual renal and peritoneal dialysis clearance are not
equivalent and thus not simply additive.8 In this prospective
randomized controlled study, increasing peritoneal solute
clearance showed no beneficial effect on survival in peritoneal
dialysis patients as a whole or in the subgroup of anuric
patients. Rather, residual renal function was predictive of
outcome. This suggests that apart from providing small
solute clearance, residual renal function has other important
metabolic effects that may not be simply replaced by
increasing the peritoneal small solute clearance and that
may also explain the survival benefits it confers in dialysis
patients. Although patients with and without residual renal
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function are simply at different stages of progressive renal
failure, our recent study showed that anuric peritoneal
dialysis patients indeed had more adverse metabolic and
cardiovascular profile as evidenced by more severe anemia
with greater erythropoietin resistance, higher calcium pho-
sphorus product, more inflammation and malnutrition,
more hypertension, and greater cardiac hypertrophy, com-
pared to patients with preserved residual renal function, and
thus explained the greater overall and cardiovascular
mortality observed in anuric patients.9 Figure 1 provides an
overview of the importance of residual renal function in
dialysis patients.
RESIDUAL RENAL FUNCTION IN RELATION TO VOLUME
CONTROL AND CARDIAC HYPERTROPHY
Residual renal function has been increasingly implicated to
be important in maintaining fluid balance of dialysis patients,
especially in patients on peritoneal dialysis. Greater extra-
cellular fluid was observed in peritoneal dialysis patients with
residual glomerular filtration rate below 2 ml/min than those
with residual glomerular filtration rate above 2 ml/min.10 In
the reanalysis of the CANUSA study, every 250 ml urine
output was associated with a 36% reduction in overall
mortality. In addition, the presence of urine output displaced
renal small solute clearance from the multivariable Cox
regression model.5 This gave indirect evidence that the degree
of sodium and water removal by the diseased kidneys
remains very important in determining the survival of
peritoneal dialysis patients. Study by Ates et al.11 also
confirmed the importance of total sodium and fluid removal
in predicting survival of peritoneal dialysis patients. Indeed,
peritoneal dialysis patients who had a history of volume
overload were noted to have more severe cardiac hypertrophy
and dilatation as well as worse systolic and diastolic
function.12 Given that cardiac hypertrophy is an important
predictor of mortality in dialysis patients, our recent findings
of more severe cardiac hypertrophy and dilatation as well as
worse cardiac function among anuric peritoneal dialysis
patients13 suggest that worsening volume control with loss of
residual renal function may indeed be one of the important
contributing factors for the adverse cardiovascular outcomes
observed in anuric patients. As shown by Wang et al.13 and
Menon et al.,14 blood pressure control worsened with time on
peritoneal dialysis as residual renal function declines, and
may be partly attributed to poor fluid control. In addition,
loss of residual renal function was associated with more
severe anemia owing to the loss of erythropoietin production,
greater degree of hypoalbuminemia, and higher arterial pulse
pressure,13 all of which were important risk factors for
cardiac hypertrophy in dialysis patients. This suggested that
the link between loss of residual renal function and cardiac
hypertrophy in peritoneal dialysis patients may involve
factors other than volume control. Residual renal function
may also play a role in limiting cardiac hypertrophy by
improving the overall removal of uremic toxins. This is
evident by the increase in cardiac mass with decline in renal
function in pre-dialysis chronic kidney disease patients,15 as
well as the regression of cardiac hypertrophy and improve-
ment of cardiac function in patients initiating continuous
ambulatory peritoneal dialysis.16 The finding that residual
renal function but not peritoneal dialysis small solute
clearance showed a significant association with cardiac hyper-
trophy,13 together with regression of cardiac hypertrophy
post-kidney transplant,17 suggests that some non-dialyzable
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Figure 1 | Importance of residual renal function in dialysis patients.
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uremic toxins may be important in mediating the progres-
sion of left ventricular hypertrophy in peritoneal dialysis
patients and needs further evaluation.
On the other hand, the importance of residual renal
function in maintaining volume control and its relationship
with cardiac hypertrophy are less well appreciated in
hemodialysis patients, although the amount of extracellular
water has also been described to be associated with hyper-
tension and left ventricular hypertrophy in hemodialysis
patients.18
IMPORTANT LINK BETWEEN RESIDUAL RENAL FUNCTION,
PHOSPHORUS CONTROL, AND CALCIFICATION
Vascular/valvular calcification is an important complication
in dialysis patients and is largely attributed to deranged
mineral metabolism with a resulting abnormally increased
calcium and phosphorus product. Cardiac valvular calcifica-
tion predicts mortality and cardiovascular death in peritoneal
dialysis patients.19 Vascular calcification is also associated
with a greater mortality risk in hemodialysis patients.20
According to the study by Block et al.,21 a 6% increase in
mortality risk was observed in hemodialysis patients for every
0.3 mmol/l increase in serum phosphate. Patients with serum
phosphate of 2.1–2.5 mmol/l had an 18% higher mortality
risk, whereas those with 2.6–5.5 mmol/l had a 39% higher risk
of mortality than those with 1.5–1.8 mmol/l. Although
continuous peritoneal dialysis is conventionally regarded to
be better in controlling hyperphosphatemia than intermittent
hemodialysis,22 our recent survey showed that hyperpho-
sphatemia is also a frequent complication in peritoneal
dialysis patients.23 Up to one-third of the peritoneal dialysis
patients with preserved residual renal function and nearly
half of the anuric patients were found to be hyperphospha-
temia. Of more importance is the finding that the degree of
residual glomerular filtration rate, despite average being
below 2 ml/min per 1.73 m2, remained strongly associated
with phosphorus control in peritoneal dialysis patients. Even
though peritoneal dialysis clearance contributes significantly
to the phosphorus control in peritoneal dialysis patients, our
study clearly demonstrated the limitation of peritoneal
dialysis alone in achieving adequate phosphorus control in
anuric patients taking the Dialysis Outcome Quality Initiative
(DOQI)-recommended dietary protein of at least 1 g/kg per
day. The poor phosphorus control together with the greater
inflammatory response in anuric peritoneal dialysis patients
in turn translated to a greater calcification risk profile and
thus predisposed to a higher incidence of valvular calcifica-
tion, more arterial stiffening, and greater degree of cardiac
hypertrophy, as shown in our recent unpublished observa-
tion. It is of interest to note that serum fetuin-A, a recently
identified circulating inhibitor of calcification as well as a
negative acute-phase reactant, showed no association with
residual renal function,24 indicating that the increased risk of
valvular calcification in anuric peritoneal dialysis patients is
unlikely to be mediated via depletion of serum fetuin-A. On
the other hand, there is so far no study that examined the
importance of residual renal function in phosphorus control
and calcification risk in hemodialysis patients.
LINK BETWEEN RESIDUAL RENAL FUNCTION AND
INFLAMMATION
Inflammation is highly prevalent in patients on dialysis, with
a reported prevalence of around 12–65%.25 The degree of
inflammation as denoted by C-reactive protein26,27 or other
proinflammatory cytokines such as interleukin-628,29 is well
established to be a powerful predictor of mortality and
cardiovascular death in dialysis patients. Loss of residual
renal function was associated with an increased inflammatory
response as denoted by C-reactive protein30 or soluble
vascular cell adhesion molecules31 in prevalent peritoneal
dialysis patients. In incident peritoneal dialysis patients,
lower residual renal function was also associated with
increased inflammation.32 Likewise, study in pre-dialysis
chronic kidney disease patients has reported a similar inverse
relationship between renal function and pro-inflammatory
mediators.33 Although the exact mechanism of association
remains to be elucidated, the study has indicated that the
relationship between residual renal function and inflamma-
tion is largely independent of the cardiovascular status of
patients.34 Loss of residual renal function or uremia per se
may enhance an inflammatory response via increased
oxidative stress and this may lead to monocyte activation
and cytokine production.35 The kidneys may play an
important role in cytokine handling, as evidenced by the
impaired cytokine clearance in nephrectomized rats.36
Conversely, the presence of inflammation also accelerated
the decline of residual renal function.37 Nonetheless,
irrespective of the underlying mechanisms of associations,
our recent study showed that the loss of residual renal
function together with inflammation and cardiac hypertro-
phy were closely interrelated phenomenon and they showed
combined additive effects in enhancing the mortality and
cardiovascular death risk of peritoneal dialysis patients.32
Using soluble vascular cell adhesion molecule as a marker of
inflammation and endothelial activation, our recent study
indicated that the association between loss of residual renal
function and higher mortality and cardiovascular event risk
was indeed mediated via its close associations with
inflammation and endothelial activation.33
RESIDUAL RENAL FUNCTION AND NUTRITIONAL STATUS
Residual renal function is important in maintaining the
nutritional status of dialysis patients. Study in peritoneal
dialysis patients has clearly demonstrated the importance of
residual renal function in determining the dietary protein
and energy intake estimated using the food frequency
questionnaire.38 Residual renal function contributes signifi-
cantly to the overall nutritional status assessed using sub-
jective global assessment,33 handgrip strength,39 or lean body
mass40 in either hemodialysis or peritoneal dialysis patients.
Micronutrients intake including those of water-soluble and
fat-soluble vitamins and other minerals is also influenced by
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the degree of residual renal function.41 It is of importance to
note that in all these studies, peritoneal dialysis urea
clearance, when considered as a separate factor, showed no
independent relationship with nutritional status assessed
using subjective global assessment, handgrip strength, or
actual dietary intake by food frequency questionnaire in
peritoneal dialysis patients. This provides important evidence
that renal and peritoneal clearance have differential effects on
nutritional status of peritoneal dialysis patients. Whether it is
related to their differential effects on clearance of middle-
molecular uremic toxins remains to be evaluated.
On the other hand, there is recent evidence that loss of
residual renal function also contributes significantly to
malnutrition in peritoneal dialysis patients via its close
association with increased resting energy expenditure.42
Resting energy expenditure accounts for 60–80% of the total
energy expenditure. Its sustained increase may lead to energy
imbalance and malnutrition if not compensated for by an
increase in energy intake. In our recent study, increased
resting energy expenditure was predictive of higher mortality
and cardiovascular death in chronic peritoneal dialysis
patients and was largely mediated via its close association
with loss of residual renal function. Resting energy
expenditure was not only increased in patients with under-
lying cardiovascular disease or more specifically in patients
with the malnutrition–inflammation–atherosclerosis syn-
drome, but also showed a strong inverse relationship with
loss of residual renal function in peritoneal dialysis patients.
No association was however observed between resting energy
expenditure and peritoneal dialysis clearance. In healthy
subjects, the kidneys may account for up to 20% of the total
resting energy expenditure. Although the effect of kidney
failure on resting energy expenditure has remained con-
troversial, our study provided evidence that despite loss of
excretory functions, the diseased kidneys in end-stage renal
disease patients retained important metabolic functions, as
evidenced by the strong negative association between loss
of residual renal function and resting energy expenditure in
peritoneal dialysis patients. In addition, our study suggested
that increased resting energy expenditure should be con-
sidered as a composite component of the malnutrition–
inflammation–atherosclerosis syndrome that frequently
accompanies patients with loss of residual renal function
and contributes to malnutrition in anuric peritoneal
dialysis patients. Further prospective study is needed to
investigate whether a decline in residual renal function is
indeed associated with an increase in resting energy
expenditure.
RESIDUAL RENAL FUNCTION AND REMOVAL OF MIDDLE
MOLECULES AND OTHER UREMIC TOXINS
The other major aspect why renal and peritoneal dialysis
clearance cannot be assumed to be equivalent lies in their
differential capacity to remove middle molecules or other
protein-bound uremic toxins. Residual renal function plays
an important role in middle molecule clearance. Irrespective
of the modality of dialysis, patients with significant residual
renal function showed lower b2-microglobulin than those
with no residual renal function.43–45 A recent study by
Bammens et al.46 provided evidence that although increasing
peritoneal dialysis clearance may enhance clearance of water-
soluble small solute clearance in patients with a decline in
residual renal function, this was not the case for middle
molecules and other protein-bound uremic toxins. Clearance
of the protein-bound solute such as P-cresol has been shown
to be largely determined by residual renal function in
peritoneal dialysis patients, and its acumulation contributes
to the uremic symptoms observed in peritoneal dialysis
patients.47
RESIDUAL RENAL FUNCTION AND QUALITY OF LIFE
Given the diversified functions of residual renal function and
its persistent important contribution to the overall health of
dialysis patients, it is not surprising to find that residual renal
function also contributes significantly to the quality of life of
dialysis patients. As shown by the NECOSAD study,48
residual renal function and peritoneal dialysis clearance had
very different impact on the quality of life of peritoneal
dialysis patients. The presence of residual renal function had
a positive influence on most dimensions of quality of life,
especially physical functioning, vitality, kidney disease-
specific symptoms, effect of kidney disease on daily life and
sleep disorders in peritoneal dialysis patients, whereas
peritoneal dialysis clearance showed no effects on any of
the quality of life dimensions.
STRATEGIES FOR PRESERVING RESIDUAL RENAL FUNCTION
One potential strategy to preserve residual renal function
may be to preferentially use peritoneal dialysis over
hemodialysis in all incident patients with residual renal
function. This concept is supported by a number of previous
studies showing the superiority of peritoneal dialysis
compared to hemodialysis in preserving residual renal
function, although these studies were mostly observational
and nonrandomized.49–52 The superiority of peritoneal
dialysis remained even after selection bias (informative
censoring) was ruled out.51 The exact mechanism of this
finding is not clear, but may relate to greater hemodynamic
stability with peritoneal dialysis and thus fewer ischemic
insults to the kidney as well as greater nephrotoxic effects of
inflammatory mediators from the extracorporeal circulation
with hemodialysis. In fact, the better preservation of residual
renal function in patients on peritoneal dialysis compared to
hemodialysis has led to the adoption of an ‘integrative care
approach’ where patients are started on peritoneal dialysis
first, then transferred to hemodialysis when peritoneal
dialysis-related problems arise. In one of the largest retro-
spective analyses, transfer of peritoneal dialysis patients to
hemodialysis was indeed accompanied by an increase in
survival compared to those remaining on peritoneal
dialysis.53 A matched-pair analysis further indicated a
survival advantage for patients adopting the integrative care
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approach compared to patients started on and remained on
hemodialysis.53 On the other hand, patients using high-flux
biocompatible membrane and ultrapure water for hemodia-
lysis were noted to have a similar decline in residual renal
function that was similar in rate to that in patients on
continuous ambulatory peritoneal dialysis.54 This gave
evidence that the greater decline of residual renal function
in patients on hemodialysis may indeed be attributed to the
use of bioincompatible membranes. Hemodialysis using
modern synthetic membranes such as high-flux polysulfone
membranes has been associated with a reduced rate of decline
in residual renal function compared to those dialyzed using
bioincompatible cellulosic membranes.55–57 Ultrapure dialy-
sis fluid has also been shown to slow the loss of residual renal
function in incident dialysis patients.55 Foreign material such
as bioincompatible membrane in contact with the blood may
activate peripheral blood mononuclear cells, resulting in
activation of complement and inflammatory cascade and
thus lead to further kidney injury.56 In other words, dialysis
using biocompatible membrane and ultrapure water may be
useful in reducing the loss of residual renal function in
hemodialysis patients.
Some earlier studies suggested a greater decline in residual
renal function with automated peritoneal dialysis compared
to continuous ambulatory peritoneal dialysis,57,58 and was
hypothesized to be related to less stable fluid and osmotic
load together with intermittent nature of automated
peritoneal dialysis. Other study showed no association
between the mode of peritoneal dialysis and loss of residual
renal function.52 In a recent review by Van Biesen,59 it was
pointed out that the association observed may be owing to
some selection bias in patients receiving automated perito-
neal dialysis. Another more recent study performed in
incident peritoneal dialysis patients also observed greater
loss of residual renal function with automated peritoneal
dialysis compared to continuous ambulatory peritoneal
dialysis.60 Further study is needed to clarify whether the
mode of peritoneal dialysis influences the rate of decline of
residual renal function.
Avoiding the use of contrasts or nephrotoxic agents such
as non-steroidal anti-inflammatory drugs or aminoglycoside
appears a reasonable approach in protecting residual
renal function. If contrast study is not avoidable, then
preventive measures including adequate hydration, use of the
smallest possible dose of contrast, use of iso-osmolal non-
ionic radiocontrast61 as well as prophylactic acetylcys-
teine62,63 should be considered. Although some earlier study
suggested that aminoglycosides may increase loss of residual
renal function,64 more recent study could not detect an
association between aminoglycoside use and decline in
residual renal function.65 Another recent randomized con-
trolled study performed in peritoneal dialysis patients with
peritonitis also indicated no greater loss of residual renal
function in patients treated with aminoglycoside compared
to those treated with ceftazidime within a 6-week duration,66
and may be explained by the intermittent, once daily dosing
regimen of netilmicin, which has been shown to be less
nephrotoxic.67
In terms of drug therapy, diuretics have been shown to
increase sodium and water excretion and improve fluid
balance in dialysis patients with residual renal function, but
there is so far no evidence that it preserves residual renal
function.68,69 Blockade of the renin–angiotensin system by
angiotensin-converting enzyme inhibition or angiotensin
receptor antagonism is a well-established approach for
renoprotection in pre-dialysis chronic kidney disease pa-
tients. One recent open-label randomized controlled study
showed that angiotensin-converting enzyme inhibitor, rami-
pril, may slow the rate of decline in residual renal function by
close to 1 ml/min per 1.73 m2 per year in patients on
continuous ambulatory peritoneal dialysis and reduce the
progression to anuria.70 Similar results were also reported
with the use of angiotensin receptor antagonist, valsartan, in
patients on continuous ambulatory peritoneal dialysis.71
Although these two studies were both very small, they do add
important supporting evidence that drugs with renoprotec-
tive effects in patients with stage 1–4 chronic kidney disease
continue to exert renoprotection benefits and slow the
progression to anuria in stage 5 chronic kidney disease
patients on dialysis and thus should be continued in all
dialysis patients with residual renal function. Maintaining
good blood pressure control should also serve as an
important measure in preserving residual renal function in
dialysis patients, given the ample positive evidence in patients
with chronic kidney disease. However, there is recent
suggestion that strict volume control in peritoneal dialysis
patients by severe salt restriction with progressive ultrafiltra-
tion till symptomatic may increase the risk of intravascular
volume depletion and further compromise residual renal
function.72 This indicates the importance to avoid over-
zealous ultrafiltration and intra-dialytic hypotension while
trying to achieve fluid balance in dialysis patients, as this may
have detrimental effects on residual renal function.
CONCLUSIONS
There is convincing evidence that residual renal and
peritoneal dialysis clearance cannot be assumed to be
equivalent in peritoneal dialysis patients. Apart from
providing small solute clearance, residual renal function
continues to serve important metabolic and hemodynamic
functions, and plays a crucial role in maintaining the overall
cardiovascular health, nutritional status, and well-being of
patients on dialysis, especially peritoneal dialysis, although
the importance of residual renal function in hemodialysis
patients is less well appreciated. Residual renal function has
also been shown to have a significant impact on the survival
of dialysis patients, especially in peritoneal dialysis, and its
loss cannot simply be replaced by increasing the dose of
peritoneal dialysis. It is time to realize that residual renal
function is a very valuable asset to patients on dialysis and
that the important goal to preserve residual renal function
should continue even after patients are started on dialysis
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treatment. More attention should be focused on preserving
residual renal function in end-stage renal disease patients
receiving long-term dialysis therapy.
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